Robin Michelet

1.0k total citations
65 papers, 703 citations indexed

About

Robin Michelet is a scholar working on Pharmacology, Epidemiology and Molecular Biology. According to data from OpenAlex, Robin Michelet has authored 65 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pharmacology, 15 papers in Epidemiology and 13 papers in Molecular Biology. Recurrent topics in Robin Michelet's work include Antibiotics Pharmacokinetics and Efficacy (27 papers), Pharmacogenetics and Drug Metabolism (9 papers) and Pharmaceutical studies and practices (7 papers). Robin Michelet is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (27 papers), Pharmacogenetics and Drug Metabolism (9 papers) and Pharmaceutical studies and practices (7 papers). Robin Michelet collaborates with scholars based in Germany, Belgium and Australia. Robin Michelet's co-authors include Charlotte Kloft, Wilhelm Huisinga, An Vermeulen, Jan Van Bocxlaer, Gerd Mikus, Madelé van Dyk, Neeltje Steeghs, Oliver Scherf‐Clavel, Ulrich Jaehde and Stefanie L. Groenland and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Antimicrobial Agents and Chemotherapy and Pharmaceutical Research.

In The Last Decade

Robin Michelet

58 papers receiving 697 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin Michelet Germany 13 187 164 128 111 98 65 703
Christian Laveille France 14 202 1.1× 120 0.7× 117 0.9× 176 1.6× 102 1.0× 33 1.0k
Yamin Shu China 17 175 0.9× 120 0.7× 207 1.6× 58 0.5× 51 0.5× 42 872
Dong‐Seok Yim South Korea 21 262 1.4× 322 2.0× 213 1.7× 134 1.2× 154 1.6× 112 1.3k
Nynke G L Jager Netherlands 15 266 1.4× 123 0.8× 85 0.7× 47 0.4× 92 0.9× 38 719
Robert R. LaBadie United States 21 87 0.5× 234 1.4× 191 1.5× 67 0.6× 120 1.2× 51 1.0k
Takafumi Kuzuya Japan 16 154 0.8× 155 0.9× 133 1.0× 131 1.2× 69 0.7× 43 716
Chantal Le Guellec France 21 223 1.2× 213 1.3× 286 2.2× 284 2.6× 134 1.4× 59 1.3k
Hua Ling United States 19 82 0.4× 176 1.1× 103 0.8× 111 1.0× 32 0.3× 65 1.0k
Maobai Liu China 17 97 0.5× 125 0.8× 225 1.8× 36 0.3× 64 0.7× 87 815
Aurélie Prémaud France 15 83 0.4× 143 0.9× 127 1.0× 284 2.6× 100 1.0× 26 934

Countries citing papers authored by Robin Michelet

Since Specialization
Citations

This map shows the geographic impact of Robin Michelet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Michelet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Michelet more than expected).

Fields of papers citing papers by Robin Michelet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Michelet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Michelet. The network helps show where Robin Michelet may publish in the future.

Co-authorship network of co-authors of Robin Michelet

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Michelet. A scholar is included among the top collaborators of Robin Michelet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Michelet. Robin Michelet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Klose, Martina, Simon Haefliger, Manuela Rabaglio, et al.. (2025). 35P TLD-1 – A novel liposomal doxorubicin formulation, in patients with advanced solid tumors: Final results of a multicenter, open-label, cross-over phase I study (SAKK 65/16). ESMO Open. 10. 104193–104193. 1 indexed citations
2.
3.
4.
5.
Allegaert, Karel, et al.. (2024). Personalized Dosing of Medicines for Children: A Primer on Pediatric Pharmacometrics for Clinicians. Pediatric Drugs. 26(4). 365–379. 4 indexed citations
6.
Michelet, Robin, et al.. (2023). Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data. Clinical Pharmacokinetics. 62(10). 1461–1477. 3 indexed citations
7.
Stegemann, Miriam, Frieder Pfäfflin, Agata Mikołajewska, et al.. (2022). Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools. Antibiotics. 11(6). 758–758. 4 indexed citations
8.
Mikus, Gerd, et al.. (2022). Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism. Pharmaceutics. 14(3). 477–477. 10 indexed citations
9.
Hohmann, Nicolas, Robin Michelet, Andreas D. Meid, et al.. (2022). Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion. Clinical Pharmacokinetics. 61(11). 1595–1607. 10 indexed citations
10.
11.
Puebla‐Osorio, Nahum, Robin Michelet, Michael R. Green, et al.. (2021). Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers. 13(11). 2782–2782. 30 indexed citations
12.
Neumann, Uta, Oliver Blankenstein, Uwe Fuhr, et al.. (2021). Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling. European Journal of Endocrinology. 185(3). 365–374. 9 indexed citations
13.
Busse, David, Philipp Simon, David Petroff, et al.. (2021). Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients. Clinical Pharmacokinetics. 61(5). 655–672. 10 indexed citations
14.
Schroth, Werner, Thomas E. Mürdter, Robin Michelet, et al.. (2020). Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clinical Pharmacology & Therapeutics. 108(3). 661–670. 21 indexed citations
15.
Michelet, Robin, et al.. (2020). Perspectives on Model‐Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations. Clinical Pharmacology & Therapeutics. 109(1). 29–36. 52 indexed citations
16.
Melin, Johanna, Zinnia P. Parra‐Guillén, Robin Michelet, et al.. (2020). Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. 105(4). e1729–e1740. 19 indexed citations
17.
Michelet, Robin, Pauline De Bruyne, Charlotte Van Herzeele, et al.. (2020). Desmopressin oral lyophilisate in young children: new insights in pharmacokinetics and pharmacodynamics. Archives of Disease in Childhood. 106(6). 597–602. 5 indexed citations
18.
Carvalho‐Wodarz, Cristiane de Souza, et al.. (2020). Decoding (patho-)physiology of the lung by advanced in vitro models for developing novel anti-infectives therapies. Drug Discovery Today. 26(1). 148–163. 6 indexed citations
19.
Michelet, Robin, Charlotte Van Herzeele, Pauline De Bruyne, et al.. (2019). An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?. Clinical Pharmacokinetics. 59(1). 81–96. 6 indexed citations
20.
Mikus, Gerd, et al.. (2019). Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metabolism Reviews. 51(3). 247–265. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian Laveille Breakdown of academic impact, for papers by Yamin Shu Breakdown of academic impact, for papers by Dong‐Seok Yim Breakdown of academic impact, for papers by Nynke G L Jager Breakdown of academic impact, for papers by Robert R. LaBadie Breakdown of academic impact, for papers by Takafumi Kuzuya Breakdown of academic impact, for papers by Chantal Le Guellec Breakdown of academic impact, for papers by Hua Ling Breakdown of academic impact, for papers by Maobai Liu Breakdown of academic impact, for papers by Aurélie Prémaud
Rankless by CCL
2026